TGen is dedicated to the next revolution in health care. With the patient at its helm, TGen is guided by three core principles: integrate, translate and accelerate. On the cutting edge of translational research, TGen is where investigators are able to unravel the genetic components of common and complex diseases.

Dr. Pam Hershberger, Associate Professor at the Hillman Cancer Research, University of Pittsburgh. Hormones such as estrogen and 1,25-dihydroxyvitamin D3 play an important role in controlling cell growth; estrogen tends to promote growth, whereas vitamin D tends to inhibit growth. The goal of Dr. Hershberger’s research is to understand how such hormone responses are generated and controlled, and how they may be exploited to suppress the development or growth of lung cancer (a disease that claims the lives of more than 160,000 individuals in the United States annually). Molecules which are found to be important in regulating hormone responsiveness in our studies represent potential new targets for therapeutic intervention in lung cancer chemoprevention and treatment.

Austin Chemical Company, Inc., provides product supply, sourcing and procurement services. In its 4th decade of business, Austin continues to evolve into new areas of services and products supply and continues to expand their global relationships with suppliers that offer new technologies, while continuing to grow the valued relationships with our historical suppliers and their associated expertise.

Particle Sciences provides contract drug development services and brings nearly two decades of expertise providing an efficient suite of preformulation, formulation, analytic and manufacturing services. A responsive and collaborative approach ensures that the objectives of all clients, large and small, are successfully met on time and on budget with the highest degree of quality.

TD2 provides fully integrated drug discovery services that accelerate the isolation and optimization of targeted oncology therapeutic agents. TD2 is a biopharma service provider uniquely positioned to meet your development challenges. TD2 integrates world-class clinical and regulatory expertise with "-omic" science and provides unique drug development services aimed at minimizing the risk for clients in the Oncology drug development industry. Our platform, referred to as "De-Risk", is a comprehensive, multi-faceted solution intended to shorten development cycles for anti-cancer agents and improve their success rates.

Paracelsus, Inc. offers a range of drug development consulting services to the pharmaceutical industry through highly knowledgeable and experienced professionals with proven discipline-specific expertise. Expertise is available to Paracelsus clients in key areas including toxicology, pharmacology (including safety pharmacology), ADME/PK, veterinary pathology, and regulatory affairs (strategic and operational).

Dr. Michael Bittner is Co-Director of the Computational Biology Division at The Translational Genomics Research Institute (TGEN), Phoenix, Arizona. The Division’s goals include building models for biological systems with the purpose of facilitating translational strategies for diagnosis/prognosis and therapy and to develop predictive methodologies capable of handling high-dimensional settings involving heterogeneous, but structured, data.

Rebexsess has internationally recognized expertise in structure based drug design and a unique computational chemistry/modeling approach with proven track records and real solutions to small molecule drug discovery.